Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis.
Andus
Tilo
T
Department of Internal Medicine, Gastroenterology, Hepatology and Oncology, Klinikum Stuttgart - Krankenhaus Bad Cannstatt, Stuttgart, Germany. tandus@klinikum-stuttgart.de
Kocjan
Andreas
A
Müser
Moritz
M
Baranovsky
Andrey
A
Mikhailova
Tatyana L
TL
Zvyagintseva
Tatyana D
TD
Dorofeyev
Andrey E
AE
Lozynskyy
Yurii S
YS
Cascorbi
Ingolf
I
Stolte
Manfred
M
Vieth
Michael
M
Dilger
Karin
K
Mohrbacher
Ralf
R
Greinwald
Roland
R
D000293:Adolescent; D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000009:adverse effects; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D019804:Mesalamine / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D057240:Patient Preference; D011349:Proctitis / Q000188:drug therapy*; D012074:Remission Induction; D016037:Single-Blind Method; D013488:Suppositories; D055815:Young Adult
D000894:Anti-Inflammatory Agents, Non-Steroidal; D013488:Suppositories; D019804:Mesalamine